Nurse Practitioner Program year 2022 Reported 2021–2022 Source: CMS Open Payments, 2026 publication

Hannah McElhannon

Nurse Practitioner, Pediatrics Raleigh, NC Nurse Practitioner

NPI 1619644507 CMS profile 10736710

1520 Sunday Dr, Raleigh, NC 27607

Open in the dashboard

General payments

$1,136

64 records reported · program years 2021–2022

Research payments

$0

Paid to them · None reported · program years 2021–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Hannah McElhannon of Raleigh, NC is reported in the CMS Open Payments database as having received $1,136 across 64 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Nurse Practitioner, Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $1,120 63
2021 General $16 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Hannah McElhannon
  • Nurse Practitioner, Pediatrics median
  • Middle half of Nurse Practitioner, Pediatrics
  • National median

In program year 2025, general payments to Hannah McElhannon were reported at $0. Among 7,458 Nurse Practitioner, Pediatrics profiles paid that year, the median was $93 and the middle half received between $35 and $201.

Show as a table
Year Hannah McElhannon Nurse Practitioner, Pediatrics median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $16 $60 $23–$142 $132
2022 $1,120 $72 $27–$161 $149
2023 $0 $89 $35–$185 $160
2024 $0 $93 $34–$199 $164
2025 $0 $93 $35–$201 $169

Breakdown

Who paid General payments · program years 2021–2022
  1. UCB, Inc. $257 14 payments
  2. Eisai Inc. $141 8 payments
  3. Ironshore Pharmaceuticals Inc. $113 6 payments
  4. Corium, Inc. $112 6 payments
  5. Jazz Pharmaceuticals Inc. $95 5 payments
  6. Aquestive Therapeutics, Inc. $79 5 payments
  7. Neurelis, Inc. $70 4 payments
  8. Sunovion Pharmaceuticals Inc. $65 4 payments
  9. Tris Pharma Inc $51 3 payments
  10. Merz Pharmaceuticals, LLC $44 2 payments
  11. Other $110 7 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2022
  1. Food and Beverage $1,136 64 payments
Products named General payments · program years 2021–2022
  1. Dayvigo $141 8 payments
  2. JORNAY PM $113 6 payments
  3. Azstarys $112 6 payments
  4. Nayzilam $92 5 payments
  5. Fintepla $91 4 payments
  6. SYMPAZAN $79 5 payments
  7. Briviact $75 5 payments
  8. Epidiolex $72 4 payments
  9. VALTOCO $70 4 payments
  10. APTIOM $65 4 payments
  11. Other $228 13 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

64 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record